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Mesoporous silica nanoparticles grafted with light-
responsive protein shell for highly cytotoxic 
antitumoral therapy. 
 
Marina Martínez-Carmonaa, Alejandro Baezaa,* Miguel A. Rodriguez-Millab, 
Javier García-Castrob and Maria Vallet-Regía.* 
A novel phototriggered drug delivery nanocarrier which exhibits very high tumor cytotoxicity against 
human tumoral cells is presented. This device is based on mesoporous silica nanoparticles decorated with 
a biocompatible protein shell cleavable by light irradiation. The proteins which compose the protein shell 
(avidin, streptavidin and biotinylated transferrin) acts as targeting and capping agents at the same time, 
avoiding the use of redundant systems. The light responsive behavior is provided by a biotinylated 
photocleavable cross-linker covalently grafted on the mesoporous surface which suffers photocleavage 
by UV radiation (366 nm). Human tumoral cells incubated in the presence of a very low particle 
concentration enter into apoptotic stage after a short irradiation time. Thus, the system here described 
could be applied for the treatment of exposed tumors that affect to skin, esophagous, stomach, among 
others, which can be easily accesible for light irradiation.  
Introduction 
In the recent years, nanoparticles with a size range of 1-500 nm have 
offered a novel alternative to traditional therapy in oncology.[1] Most 
of the conventional chemotherapeutic agents have poor 
pharmacokinetic profiles and are distributed non-specifically in the 
body, leading to systemic toxicity associated with serious side 
effects.[2] Therefore, great efforts have been carried out for the 
development of nanocarriers able to transport and deliver multiple 
therapeutic agents, specifically to defined target cells without 
affecting the healthy ones.[3] Tumor blood vessels are different to 
normal ones; due to its rapid and chaotic growth, they have abnormal 
architectures which present large fenestrations with diameters up to 
few hundred nanometers, being highly permeable. This anatomical 
defectiveness promotes the extravasation of nanoparticles through 
these pores causing their tumoral tissue accumulation.[4] Moreover, 
the slow venous return and the poor lymphatic clearance 
characteristic of neoplastic tissues mean that particles remain trapped 
during longer times. Both behaviors, high permeability and poor 
lymphatic drainage, constitute the gold standard of the use of 
nanoparticles for antitumoral therapy because they lead to a passive 
accumulation of the nanocarriers within the tumoral tissue by a 
phenomenon called EPR effect (enhanced permeability and 
retention).[5] To improve the selectivity of the nanoparticles against 
the diseased cells, the external surface of the nanoparticles can be 
decorated with different molecules able to be selectively recognized 
by the tumoral cells as antibodies, proteins, oligonucleotides or small 
molecules, among others.[6] Additionally, if drug release takes place 
once internalized within the tumoral cell, the cytotoxic effect of the 
released drug could be stronger as a consequence of the reduced 
volume of the cell. This behavior may be achieved using stimuli-
responsive nanodevices able to release their therapeutic payloads 
only in the presence of certain stimulus.[7] Mesoporous silica 
nanoparticles (MSN) have attracted much attention because of their 
unique properties.[8-10] Additionally, this material can be 
functionalized with stimuli-responsive gatekeepers placed outside 
the pore openings in order to control or trigger the drug release by 
the presence of a specific stimulus.[11] Thus, many inorganic or 
organic moieties such as nanocrystals,[12] DNA,[13] proteins,[14] 
polymers[15] or small molecules,[16,17] among others have been 
employed as responsive gates to different stimuli. Among these 
stimuli, light is a powerful tool because it presents low toxicity and 
its application can be spatially and temporally controlled by finely 
selecting the area and the exposure time.[18,19] Moreover, light can be 
locally applied to internal tumor areas using optic probes. Fujiwara 
et al.[20] described by the first time the use of light sensitive MSN 
ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
placing coumarin molecules on the pore outlets. These molecules 
suffer dimerization which blocks the pore in a reversible way in 
response to light irradiation. Later, other moieties have been grafted 
on MSN surface using light-cleavable bonds.[21-23] However, it has 
been observed that certain capping agents (metal nanoparticles, 
dendrimers, cationic polymers, etc.) themselves may cause cytotoxic 
damage to host.[24-26] Proteins are compatible with biological 
systems, biodegradable, nontoxic and non-immunogenic as well as 
very stable, and really specific.[27] Herein, we propose a novel 
photosensitive drug delivery nanocarrier based on mesoporous silica 
particles covered with a photosensitive protein shell cleavable by 
light irradiation. Moreover, in order to avoid the use of redundant 
systems, the external protein layer acts as targeting and capping 
agents at the same time (Figure 1). 
 
 
Figure 1. Schematic illustration of the action mechanism of the light-responsive device 
 
MSN surface was decorated with a light-sensitive cross-linker 
whose biocompatibility has been also proved (both the residues 
before and after photocleavage)[28] which carried biotin 
moieties. Thus, the proteins which compose the protein shell 
(avidin, streptavidin and biotinylated transferrin) were attached 
on the MSN surface by avidin/streptavidin-biotin interactions. 
The supramolecular interaction between avidin or streptavidin 
and biotin is one of the strongest non-covalent biological 
interaction known (Kd = 4 x 10-14 M), being the bond formed 
very rapidly and keeping stable in wade ranges of pH and 
temperature.[29-31] The targeting capacity of the device was 
provided by the attachment of transferrin (Tf) molecules on the 
MSN surface using previously biotinylated transferrin. The 
transferrin receptor functions in cellular iron uptake through its 
interaction with Tf. This receptor is an attractive molecule for 
the targeted therapy of cancer since it is upregulated on the 
surface of many cancer types.[32-34] It has been widely reported 
that the presence of transferrin in the surface displays 
enhancement in particle uptake of different nanosystems into 
human cells. [35-38] It is important to highlight the simplicity of 
our device where the protein shell perform a dual function as 
gatekeeper and targeting agent at the same time. The 
nanodevice here presented corresponds to a proof of concept of 
the potential antitumoral clinical applications of these types of 
systems. Finally, the presence of photocleavable biotins on the 
surface introduces high versatility due to it is also possible to 
attach other targeting agents and therapeutic macromolecules 
using biotin-streptavidin bridges.  
 
Results and Discussion 
Synthesis of biotinylated MSN 
For this purpose, MSN were prepared according to a modified 
Stöber method producing round shaped particles with diameters 
around 120 nm.[39] For the synthesis of the photosensitive cross-
linker, biotin was coupled with the commercially available 
photolinker previously deprotected (PhoL1) using carbodiimide 
chemistry. Once isolated the biotin-photolinker compound 
(PhoL2) aminopropyltriethoxysilane (APTES) was reacted with 
the activated acid group using a similar strategy, producing the 
final compound (PhoL3). The reaction product was confirmed 
by 1H-NMR (Figure 2).  
 
 
 
Figure 2. Scheme of synthesis and H-NMR spectrum of PhoL3. i) piperidine / DMF 
(20%), ii) (+)-Biotin N-hydroxysuccinimide ester, iii) APTES 
 
 
The appearance of a new signal at 8.5 ppm due to the amide 
formation between the amino group of the biotin and the 
carboxylic acid of the PhoL was observed (green arrow). It is 
also possible to observe that the nearest methylene protons 
(CH2, red arrow and CH, purple arrow) of the new amide bonds 
shift to lower fields. Additionally, the methylene group close to 
carbonyl (blue arrow) suffers shift to higher fields as a 
consequence of the new amide bond formation (For complete 
proton assignment see (Figure S1-3).  The formation of PhoL3 
was also confirmed by FTIR and mass spectrometry (Figure S4 
and S5). MSN surface was decorated with PhoL3 by refluxing 
in toluene during 12 hours in darkness conditions producing the 
functionalized particles (MSN-B).  
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[Ru(bipy)3]Cl2 loading and capping 
To test the feasibility of the light-responsive behavior 50 mg of 
MSN-B were loaded with [Ru(bipy)3]Cl2 as fluorophore for 36 
hours.  After that, particles were capped with streptavidin, 
avidin and biotinylated transferrin which were added 
sequentially at 1 hour intervals and finally allowed to react 
overnight in a refrigerator (Scheme 1).  
 
 
 
Scheme 1. Synthesis of the nanocarrier MSN-Tf. i) PhoL3, ii) [Ru(bipy)3]Cl2 or Dox, 
iii) streptavidin, iv) avidin, biotinylated transferrin. 
 
 
Avidin was employed in order to bind to the excess of the biotin non 
complexed with streptavidin guarantying the pore capping. The 
excess [Ru(bipy)3]Cl2 was removed by filtration, centrifugation and 
washing with water. The product, MSN-Tf-Ru, was dried in a N2 
flow.   
 
Light-responsive release 
In order to monitor the light-responsive behavior, two batches of 
MSN-Tf-Ru particles were suspended in water and one of them was 
exposed to 366 nm irradiation for 15 min and stirred during 1h. The 
other batch was treated under similar conditions but without light 
irradiation. The amount of fluorophore released was determined by 
fluorescence measurements of the solutions, (ex = 451 nm, em = 
619 nm). The released dye for both the irradiated and non-irradiated 
samples is shown in Figure 3a showing a remarkable fluorescence 
increase in the case of the illuminated sample. This experiment was 
carried out twice displaying similar results. To ensure that the drug 
release is triggered by the light-induced protein shell removal, the 
previous experiment was repeated but without dye loading of MSN-
B and using fluorescent labeled Tf which allows an easy 
monitorization of the uncapping process by fluorescence 
spectroscopy. Similar to the previous case, the observed fluorescence 
with irradiated sample was markedly higher than the sample 
remained in darkness (Figure 3b). 
 
Figure 3. a) [Ru(bipy)3]Cl2 release of MSN-Tf-Ru and b) fluorescent labeled Tf release 
from MSN-Tf in the absence of light and upon UV light irradiation. 
MSN-Tf characterization 
In order to perform a better characterization of the complete 
material, MSN-Tf was synthesized without loading dyes.  
MSN, MSN-B and MSN-Tf were characterized by different 
techniques and the results compared after each reaction step. By 
FTIR spectroscopy we were able to follow the nanoparticle 
coating process. The change from a clean spectrum in the 1500-
2000 cm-1 range of MSN to the presence of two signals at 1637 
and 1519 cm-1 characteristic of PhoL3 in MSN-B was observed 
(Figure S6). Finally in the FTIR spectrum of MSN-Tf, a 
broadening of the bands mentioned above as well as a clear 
increase in intensity corresponding to the presence of a greater 
number of amide bonds is appreciated. The functionalization 
degree of the particles was calculated by difference between 
thermogravimetric analysis (TGA) measures finding 16% of 
PhoL3 in MSN-B and 6% of protein shell in the final system 
MSN-Tf.  As it would be expected, the pore volume of the 
mesoporous silica material suffers a significant decrease with 
increasing surface decoration. Thus, the specific surface area 
changes from 952 in the case of naked material (MSN) to 121 
m2/g, in the case of the complete system MSN-Tf (Figure S7). 
The porosity network also experiment a significant order loss as 
a consequence of the protein shell formation (Figure S8). The 
size of the different nanoparticles was determined by dynamic 
light scattering (DLS) showing that the sized distribution 
shifted to higher values (122 to 190 nm) with increasing 
functionalization (Figure 4a). As can be observed in Figure S9 
by increasing the functionalization the sample becomes less 
homogeneous thereby increasing lightly its polydispersity index 
(PDI) (Table S2).   
 
 
 
Figure 4. a) DLS and b) Z potencial measurements of MSN materials. c-d) TEM images 
of MSN and MSN-Tf respectively 
 
Zeta potential measurements in water of these particles show 
drastic change on the superficial charge with values of -27.2, 
+0.02 and -29.3 mV for MSN, MSN-B and MSN-Tf, 
respectively (Figure 4b). This is consistent with the expected 
results because biotinylation introduce hydrophobicity on the 
surface and therefore, the surface charge in water approaches to 
i) ii)
iii)
iv)
v)
Photolinker
Streptavidin
Biotin
Transferrin
Avidin
Dye / Drug
a) b)
c) d)
a) b)
-30
-25
-20
-15
-10
-5
0
5
10
m
V
MSN
MSN-B
MSN-Tf
ARTICLE Journal Name 
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
zero. After the transferrin and avidin grafting step, the surface 
charge of the particle becomes negative again due to the 
negatively charged nature of the introduced proteins at neutral 
pH as a consequence of their isoelectric points (PI) which are 
5.5 and 6.7, respectively. Finally, it was possible to observe the 
protein shell by transmission electron microscopy (TEM). 
Figure 4c-d shows the transition from a smooth (MSN) to 
rough (MSN-Tf) surface of the particles. 
Dox loading and capping 
Once the system was fully characterized and proved to work 
properly, particles were loaded with Doxorubicin (Dox) in 
order to test their antitumoral properties using cell cultures. 
Doxorubicin was loaded into the pores of the material by 
soaking dried MSN-B in a solution of Dox (3 mg/ml) for 48h. 
After that, the system was sealed by the addition of proteins 
following the procedure previously described. The excess Dox 
was removed by filtration, centrifugation and washing with 
water. The product, MSN-Tf-Dox, was dried in a N2 flow at 
room temperature. The amount of Dox loaded in the sample 
was determined from the difference between the fluorescence 
measurements of the initial and the recovered filtrate solutions. 
The results indicate that MSN-Tf-Dox present a loading 
capacity around 7% w/w. 
 In Vitro Cytotoxicity and Cellular Uptake Evaluation 
As it was mentioned, transferrin receptor is known to be 
overexpressed in many cancer cell lines. The amount of 
transferrin receptors was determined in four different tumoral 
cell lines of Ewin tumor (A673) fibrosarcoma (HT1080) 
osteosarcoma (SAOS2) and neuroblastoma (NB1681) in order 
to select one of them which show the higher affinity by 
transferrin molecule. HT1080 tumoral cell line was chosen in 
the first trials due to transferrin receptors are expressed in the 
higher amount (Figure S10).  
In order to test the targeting capacity of the transferrin placed 
on the external surface of the carriers, HT1080 cells were 
incubated in the presence of particles functionalized with 
transferrin (MSN-Tf) and naked ones (MSN). Both type of 
particles were labeled with fluorescein through conjugation 
with fluorescein isothiocyanate (FITC) as has been previously 
reported.[40] Thus, HT1080 cells were exposed to a certain 
amount of fluorescent nanoparticles during 24 hours. The 
amount of cells which engulf particles was determined by flow 
cytometry. Particles functionalized with the protein shell show 
a five-fold increase in cell uptake in comparison with the non-
functionalized system (Figure 5a). Confocal images 
demonstrate that nanoparticles were efficiently internalized 
inside of HT1080 tumoral cells (Figure 5b). Particle 
internalization was not observed when the cells were treated 
with particles without the protein shell on the surface.  
The in vitro cytotoxicity study of the system was determined by 
the exposition of this cellular line to increased amounts of 
nanomaterials functionalized with transferrin and loaded with 
doxorubicin (MSN-Tf-Dox) with and without light irradiation 
in order to establish the minimal concentration required to 
induce significant cellular apoptosis. 
 
 
Figure 5. a) Cellular uptake of MSN and MSN-Tf labeled with fluorescein, b) Confocal 
microscopy images showing nanoparticles (green) inside of HT1080 cells (actin in red, 
nucleus in blue) The bottom and side panels show the x–z and y–z cross-sectional 
images, respectively. 
 
Cells were incubated during 24 hours in order to allow the 
particle uptake. After this time, the cells were washed with PBS 
for removing the non-internalized particles and the premature 
released drug. Then, one batch of cells was exposed to 15 min 
of light irradiation maintaining the other batch in darkness 
conditions.  
 
 
Figure 6. a) Flow cytometry of HT1080 cells treated with MSN-Tf-Dox without UV 
irradiation, stained with Annexin-V and 7-AAD. Upper number: Doses of Doxorubicin 
in g/mL b) Flow cytometry of HT1080 cells treated with MSN-Tf-Dox irradiated with 
UV light, stained with Annexin-V and 7-AAD. Upper number: Doses of Doxorubicin in 
g/mL. 
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After two days of incubation time, the cytotoxicity was 
evaluated by flow cytometry using Annexin V/7-AAD protocol 
for apoptotic cell determination. As is shown in Figure 6b, a 
clear apoptosis is seen in the 100% of cells with nanoparticle 
doses so lower as 0.01 g/mL and UV irradiation, whereas the 
samples which were maintained in darkness conditions present 
a same survival ratio than the controls (Figure 6a). The 
reported IC50 value of free doxorubicin in HT1080 cells is 
0.006 µg·mL-1.[41]  This fact means almost ten-fold enhance of 
the therapeutic efficacy of the drug due to 0.01 µg·mL-1 of 
particles release at the most 0.0007 µg·mL-1 according with the 
maximum loading mentioned above. It is important to note that 
cells were not affected by the simply exposition of UV light 
without particles. Similar results were obtained with 
nanoparticles loaded with other cytotoxic drug, oxalilplatin 
(Figure S11 and S12). Finally, the other three tumoral cell lines 
were exposed to the presence of these doxorubicin loaded 
nanoparticles in order to test if this system is able to destroy 
other tumoral cell lines which express lower amount of 
transferrin receptors on their surface (Figure S10). In all the 
cases, the cells entered in apoptotic state when equivalent 
amounts of drug loaded nanoparticles were employed under 
light irradiation conditions. These data suggest that the 
nanoparticles are able to be efficiently internalized in the cells 
independently of the amount of transferrin receptors. The 
ubiquitous nature of transferrin receptors which are present also 
in many healthy cells could be a drawback of the use of 
transferrin as targeting agent.[42,43] In our device, transferrin 
plays a dual role being a capping agent that prevents the 
premature departure of the loaded drug and a cell uptake 
enhancer. Drug departure is taking place only after light 
irradiation which could avoid the apparition of side effects in 
healthy cells as a consequence of the fact that light can be 
easily focused only in the diseased tissue. These data clearly 
indicate that nanoparticles are able to induce apoptosis at really 
low dosages which could be of great interest for oncological 
applications. 
 
Experimental Section 
Synthesis of mesoporous silica nanoparticles (MSN) 
MSN were synthesized as following: to a 1 L round-bottom flask, 1 
g of CTAB as a structure-directing agent, 480 mL of H2O (Milli-Q), 
3.5 mL of NaOH (2 M) were added. The mixture was heated to 80ºC 
and stirred at 600 rpm. When the reaction mixture was stabilized at 
80ºC, 5 mL of TEOS were added dropwise at 0.33mL/min rate. The 
white suspension obtained was stirred during further 2h at 80ºC. The 
reaction mixture was filtered and washed 3 times with 100 mL of 
H2O, and then ones with 50 mL of EtOH. Finally, the surfactant was 
removed by ionic exchange using a solution of amonium nitrate (10 
mg/mL) in 400 mL of ethanol (95%) at 65ºC overnight under 
magnetic stirring.  
 
Synthesis of fluorescent MSN 
FITC (1mg) and APTES (2,2 µL) were disolved in the 
minimum volume of EtOH and the mixture was stirring at room 
temperature for 2 hours under N2 atmosphere. The resulting 
solution was called Solution 1. 
Fluorescent MSN were synthesized following the same procedure 
used for MSN but instead of adding 5 mL of TEOS, a mixture of 5 
mL of TEOS and Solution 1 was used.  
 
Synthesis of PhoL1 
600 mg of Fmoc-photolinker were placed in a 25 mL round bottom 
flask and dissolved in 12 mL of piperidine/DMF (20%) solution. The 
flask was placed in an ultrasound bath for 1h in the absence of light 
to remove the protecting group. Solvent was evaporated in a rotavap 
using a cannula and the product was washed with ether, filtrated and 
dried in a vacuum oven at 40ºC overnight.   
 
Synthesis of PhoL2 
 200 mg of photolinker were placed in a 100 mL round bottom flask 
and dissolved in 38 mL of dry DMF. 250 mg of NHS-B were added 
and the solution was stirred in darkness at room temperature for 2 h. 
Solvent was evaporated in the rotavap using a cannula, the product 
was washed with ether, filtrated and dried in a vacuum oven at 40ºC  
overnight.   
 
Synthesis of PhoL3 
350 mg of PhoL2 were placed in a 100 mL round bottom flask and 
dissolved in 38 ml of dry DMF. To this solution, 106 mg of DCC 
and 99 mg of NHS were added and the mixer was stirred in darkness 
at room temperature for 2 h. After that 223 µL of APTES were 
added and the reaction was allow to stir for 3h at room temperature. 
The precipitated dicyclohexylurea was removed by filtration and 
solvent was evaporated in the rotavap using a cannula, the product 
was washed with ether, filtrated and dried in a vacuum oven at 40ºC 
overnight.  
 
Attachment of PhoL3 on the MSN 
 350 mg of MSN were placed in a three-neck round bottom flask and 
dried at 80ºC under vacuum for 24 h. Then, 125 mL of dry toluene 
were added and the flask was placed in an ultrasonic bath for better 
suspension of particles. After that a solution of 210 mg of PhoL3 in 
28 mL of dry DMF were added, keeping the reaction in darkness, 
under nitrogen atmosphere at 80ºC for 24h. After that time, the 
sample was filtered and washed two times with water and once with 
MeOH. Finally, the product was dried under vacuum at 40ºC.   
 
Synthesis of biotinylated Tf 
To a solution of 5 mg transferrin in 1mL of PBS 1mg of (+)-Biotin 
N-hydroxysuccinimide ester (NHS-B) dissolved in 10 L of DMSO 
was added. The solution was stirred for 2 h. The protein was purified 
by centrifugal separation with 30KDa cut-off filters (AMICON® 
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Ultra-2 30K) and washed three times with fresh phosphate buffer 
saline (PBS). The protein was concentrated to final volume of 200 
µL.  
 
Synthesis of fluorescence Tf  
1 mg of biotinylated Tf was dissolved in 1 ml of PBS buffer. Then 
10 L of a solution of 1 mg of FITC dissolved in 100 L of DMSO 
was added. The reaction mixture was stirred at 250 r.p.m. for 2 h at 
room temperature. The protein was purified by centrifugal separation 
with 50KDa cut-off filters (AMICON® Ultra-2 50K) and washed 
three times with PBS buffer. The protein was concentrated to final 
volume of 250 µL.  
 
[Ru(bipy)3]Cl2  / Dox loading and capping (MSN-Tf) 
50 mg of MSN were placed in a topaz vial and dried at 80ºC under 
vacuum overnight. Then, 7 mL of [Ru(bipy)3]Cl2 or Dox aqueous 
solution (10 or 3 mg/mL respectively) were added and the 
suspension was stirred at room temperature for 48 h. After that, 
particles were capped with 2.5 mg of streptavidin, 25 mg of avidin 
and 200 L of biotinylated transferrin and that were added 
sequentially at 1 hour intervals and finally allowed to react overnight 
in a refrigerator. Then, samples were filtered and washed two times 
with water (2x2 mL) in order to remove the [Ru(bipy)3]Cl2 or Dox 
absorbed on the external surface. Finally, the products were dried 
under vacuum at 25ºC. A similar loading procedure was employed 
with oxalilplatin drug.  
 
Cell culture 
HT-1080 human fibrosarcoma cells, were grown at 37ºC and 5% 
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum 
(FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 U/mL 
streptomycin. FBS from obtained from HyClone whereas media and 
other reagents were from Lonza. Experiments were conducted once 
cells reached 80-90% confluence.  
 
Flow cytometry analysis 
HT1080 cultures were analyzed by flow cytometry techniques. 
Basically, cultured cells were trypsinized for 5 minutes (0.5% 
trypsin plus 0.2% EDTA), washed with saline buffer (centrifugation 
at 600 g, 5 minutes, room temperature) and resuspended in 100 L 
of saline buffer. Cells were incubated with an anti-CD71 monoclonal 
antibody (M-A712 clone; BD Biosciences). As a negative control, 
cells were incubated with the same isotype immunoglobulin. After 
45 minutes incubation at 4°C in the dark cells were washed and 
resuspended in 200 L of saline buffer. 
 
For cytotoxicity studies, cells were seeded in 24 well plates (BD 
Biosciences). To test the effect of doxorubicin or oxaliplatin free 
drugs, medium was replaced with fresh medium containing 
doxorubicin (Sigma-Aldrich) and cells were further incubated for 48 
hours and subjected to flow cytometry analysis. For nanoparticle 
uptake, cells received fresh medium containing nanoparticle 
suspensions (0-10 µg/mL) and were incubated for 24 hours. To 
release the drugs out of the nanoparticles, cells were first washed 
with PBS buffer to remove nonspecific binding particles and fresh 
medium was added to the wells. Photo-responsive experiments were 
carried out using a BLAK-RAY UV bench lamp (UVP, CA, USA) 
and the cells were exposed to UV light at 365 nm for 15 min at the 
distance of ~ 5 cm whereas control plates were untreated. At 2 days 
post-irradiation, cells were harvested with a trypsin-EDTA solution, 
resuspended in PBS, stained with Annexin V-APC (BD Biosciences) 
and 7-AAD (Biolegend) and analyzed by flow cytometry. Data were 
collected using a FACS Calibur cytometer (BD Biosciences) and 
analyzed using FlowJo software (Treestar, Ashland, OR, USA).  
 
Confocal microscopy studies 
Experiments were conducted in 8-well glass slides (Millipore). 
For nanoparticle uptake, cells were incubated with medium 
containing nanoparticle suspensions (0-10 µg/mL) for 24 hours. 
The glass slide chambers were completely washed with PBS 
buffer to remove the non-internalized particles. Then, cells 
were fixed with 4% paraformaldehyde for 15 min, washed with 
PBS buffer and stained with Texas Red Phalloidin (Invitrogen). 
After staining, the slides were rinsed in PBS buffer and 
mounted in Prolong Gold with DAPI (Invitrogen). The images 
were acquired using a Leica TCS SP5 confocal microscope 
(Leica Microsystems, Wetzlar, Germany) equipped with a 63× 
(numerical aperture 1.4) oil immersion objective. Each image 
cube was optically cut into 16 sections, and the sections that cut 
through the nucleus and cytoplasm were presented. For 
presentation purposes, pictures were exported in TIFF format 
and processed with Adobe Photoshop (Mountain View, CA, 
USA), for adjustments of brightness and contrast.  
 
Conclusions 
In conclusion, a novel nanomaterial able to transport cytotoxic 
species and release them in response to light irradiation has 
been presented. In this device, a protein shell anchored on the 
particle surface through a UV-sensitive cross-linker act as 
targeting agent and cleavable gatekeeper at the same time. The 
use of proteins as pore blockers guarantee the biocompatibility 
of the nanodevice avoiding the use of exotic caps which could 
provoke toxicity issues in further clinical development steps. 
This nanocarrier can be internalized by tumoral cells thanks to 
the presence of transferrin on the external surface and once 
there, it can release enough amounts of cytotoxic species to 
initiate the apoptotic cascade in diseased cells after light 
irradiation. The cytotoxic capacity of this system was evaluated 
in vitro against several tumoral cell lines which overexpress 
transferrin receptors, showing an excellent performance being 
able to transform the diseased cells into apoptotic cells using a 
very low particle dose. The triggerable high cytotoxic capacity 
and the versatile nature of the streptavidin/biotin bridges which 
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allow the introduction of other biotinylated targeting agents, 
convert this material into a very interesting candidate for the 
treatment of exposed malignancies accessible by light 
irradiation. Despite the poor penetration of UV light in living 
tissues, this system could offer a promising alternative for the 
treatment of accessible tumors such as skin, esophagus or 
stomach in which light can be easily applicable by direct 
irradiation or through the use of optic fiber.  Further work is 
ongoing in order to test the efficacy of this device using in vivo 
murine models. 
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